RNA Polymerase III Transcription: Its Control by Tumor Suppressors and Its Deregulation by Transforming Agents

TIMOTHY R. P. BROWN, PAMELA H. SCOTT, TORSTEN STEIN,
ANDREW G. WINTER, AND ROBERT J. WHITE¹

*Institute of Biomedical and Life Sciences, Division of Biochemistry and Molecular Biology,
Davidson Building, University of Glasgow, Glasgow, G12 8QQ, UK*

The level of RNA polymerase (pol) III transcription is tightly linked to the rate of growth; it is low in resting cells and increases following mitogenic stimulation. When mammalian cells begin to proliferate, maximal pol III activity is reached shortly before the G₁/S transition; it then remains high throughout S and G₂ phases. Recent data suggest that the retinoblastoma protein RB and its relatives p107 and p130 may be largely responsible for this pattern of expression. During G₀ and early G₁ phase, RB and p130 bind and repress the pol III-specific factor TFIIB; shortly before S phase they dissociate from TFIIB, allowing transcription to increase. At the end of interphase, when cells enter mitosis, pol III transcription is again suppressed; this mitotic repression is achieved through direct phosphorylation of TFIIB. Thus, pol III transcription levels fluctuate as mammalian cells cycle, being high in S and G₂ phases and low during mitosis and early G₁. In addition to this cyclic regulation, TFIIB can be bound and repressed by the tumor suppressor p53. Conversely, it is a target for activation by several viruses, including SV40, HBV, and HTLV-1. Some viruses also increase the activity of a second pol III-specific factor called TFIIC. A large proportion of transformed and tumor cell types express abnormally high levels of pol III products. This may be explained, at least in part, by the very high frequency with which RB and p53 become inactivated during neoplastic transformation; loss of function of these cardinal tumor suppressors may release TFIIB from key restraints that operate in normal cells.

Cell cycle	p53	RB	Transformation	Transcription	TFIIB	pol III
------------	-----	----	----------------	---------------	-------	---------

RNA polymerase (pol) III is responsible for 5–10% of all nuclear transcription (91). It operates in discrete, localized transcription “factories,” which typically contain about five molecules of active pol III, but no pol I or pol II (91). Pol III synthesizes a variety of essential cellular products, including tRNA, 5S rRNA, the 7SL RNA component of the signal recognition particle, and the U6 small nuclear RNA that is required for splicing mRNA [reviewed in (126,135)]. Common features of these transcripts are that they are short (usually less than 200 bp) and are not translated.

The synthesis of pol III products is clearly an es-

sential component of cellular metabolism and, as such, can be regarded as a housekeeping function. However, although it occurs in all cells with nuclei, pol III transcription is regulated strongly in response to a variety of external stimuli [reviewed in (126)]. For example, it is tightly linked to growth conditions, increasing in response to mitogenic signals and falling when serum factors or nutrients are limiting. It is also subject to cell cycle control in vertebrates, being activated at the G₁/S transition and repressed at mitosis. Many different viruses have potent effects upon the rate of pol III transcription. Furthermore, the majority of transformed and tumor cell types display

¹Address correspondence to Robert J. White, Institute of Biomedical and Life Sciences, Division of Biochemistry and Molecular Biology, Davidson Building, University of Glasgow, Glasgow, G12 8QQ, UK. Tel: 0141-330-4628; Fax: 0141-330-4620; E-mail: rwhite@udcf.gla.ac.uk

abnormally elevated levels of pol III products. In none of these cases has evidence been found that the polymerase itself is controlled directly. Instead, regulation is mediated through changes in the activities of pol III-specific transcription factors.

THE BASAL POL III TRANSCRIPTION APPARATUS

The nuclear RNA polymerases alone have little specificity for particular DNA sequences. In the case of pol III, recruitment to specific genes requires the presence of TFIIB, a factor that binds just upstream of the transcription start site (3,49). TFIIB is a complex comprising a minimum of three subunits, one of which is the TATA binding protein (TBP) [reviewed in (34,94)]. In the yeast *Saccharomyces*, two TBP-associated factors (TAFs) are also required for TFIIB activity (50,51,95,99). One of these TAFs has substantial homology to the basal pol II factor TFIIB (9,19,75); for this reason, it is often referred to as TFIIB-related factor or BRF. The other essential TAF in yeast TFIIB has a SANT domain and is called B'' (1,51,95,99). Mammalian TFIIB is much less well characterized, with at least one unidentified subunit. Homologues of BRF have been isolated in humans, nematodes, and fruit flies (71,81,117,121), but a gene for B'' has yet to be reported outside of yeast.

A few pol III templates, such as U6 snRNA genes, have TATA sequences located ~30 bp upstream of the initiation site. This motif is recognized by TBP and therefore allows direct binding by TFIIB (47,74,78,105). However, most pol III-transcribed genes have no TATA element. In such cases, TFIIB is recruited to the promoter by protein-protein interactions with the factor TFIIC. Although TFIIC is a single entity in yeast, human TFIIC has been subdivided into two separate components, called TFIIC1 and TFIIC2 (138). Little progress has been made in characterizing TFIIC1, although sedimentation analysis suggested a mass of up to 200 kDa, assuming that it is globular (138). However, human TFIIC2 has been purified and shown to consist of five polypeptides, with a cumulative mass approaching 600 kDa (107,122,139). The cloning of cDNAs has now been reported for all of these subunits (41,42,65,66,107). A notable feature of TFIIC2 is that three of its subunits possess histone acetyltransferase activity, which may help it gain access to promoters that have been incorporated into chromatin (41,63). TFIIC2 binds directly to DNA sequences that are present within the coding regions of most pol III templates, including tRNA genes (72,138). An exception is provided by the 5S rRNA genes, where the polypeptide

TFIIIA provides a platform for TFIIC (72). Once TFIIC2 is in position, it interacts with TFIIB and brings it onto a region of DNA for which it has little or no intrinsic affinity (21,42). TFIIC1 can join the complex either before or after TFIIB is recruited (21). Once assembled, TFIIB binds the pol III enzyme and places it over the initiation site so that transcription can commence (49). Indeed, the assembly factors TFIIIA and TFIIC are no longer required after they have brought TFIIB to a promoter, at least in vitro (49). TFIIB can therefore be regarded as the pivotal initiation factor in the pol III system.

THE TUMOR SUPPRESSOR PROTEINS p53 AND RB

The key role of TFIIB can explain why it is targeted for tight control by many regulatory proteins (127). One of these is the important tumor suppressor p53, which arrests cell growth or triggers apoptosis in response to stresses such as radiation exposure, oncogenic stimuli, or hypoxia (28,58). Overexpression of p53 will repress transcription of various pol III templates both in vitro and in transfected cells (10,15). Furthermore, the synthesis of tRNA and 5S rRNA in vivo is elevated four- to sixfold following the targeted disruption of the p53 gene in knockout mice (10). TFIIB activity is abnormally elevated in fibroblasts derived from such mice (10). Cofractionation, coimmunoprecipitation, and pull-down assays have shown that TFIIB interacts with both recombinant and endogenous p53 (10,15). It therefore appears that p53 can regulate pol III transcription by binding and repressing TFIIB. It remains to be determined how this control responds to the various stress conditions that are known to influence p53 activity.

TFIIB is also bound and regulated by the tumor suppressor RB, the product of the retinoblastoma susceptibility gene (16,69,70,110). This is despite the fact that p53 and RB bear no similarity in sequence or structure. Overexpressing RB in transfected cells produces a significant decrease in pol III activity (16,132). Recombinant RB will also repress transcription that has been reconstituted in vitro using partially purified pol III factors (16,69,70,132). Perhaps most importantly, inactivation of the endogenous *Rb* gene using knockout technology results in a fivefold increase in the synthesis of tRNA and 5S rRNA in vivo (132). Extracts prepared from *Rb*-knockout mice display a specific increase in TFIIB activity (69). Recombinant RB will bind to natural or recombinant TFIIB subunits (16,69,70,110). Furthermore, the existence of endogenous complexes between cellular RB and TFIIB can be readily demon-

strated by coimmunoprecipitation assays (69,70,110). These data provide a convincing case that TFIIB is a target for repression by RB in vivo.

RB has two relatives, called p107 and p130, with which it shares 30–35% identity at the amino acid level [reviewed in (32,35,85)]. These three are referred to as the pocket proteins, because most of their homology lies within a bipartite region called the pocket domain. They can each inhibit cell growth and proliferation when overexpressed (18,92,140). A number of common target proteins have been found to interact with the pocket domains of RB, p107, and p130, including members of the E2F family of cellular transcription factors and the oncoprotein products of several DNA tumor viruses [reviewed in (24,35,85,112)]. TFIIB also falls into this category, because it binds to all three of the pocket proteins, as shown by cofractionation, coimmunoprecipitation, and pull-down assays (110). Like RB, recombinant p107 and p130 will repress transcription of a range of pol III templates both in vitro and in transfected cells (110). Furthermore, fibroblasts derived from *p107^{-/-} p130^{-/-}* double-knockout mice display elevated levels of pol III transcripts (110). The ability to bind and repress TFIIB is therefore a feature of each of the pocket proteins; this is consistent with deletion and substitution analyses which have shown that regulation of pol III transcription by RB is dependent on the pocket domain (16,132).

THE CELL CYCLE

The function of the pocket proteins is subject to cell cycle control [reviewed in (32,35,82,85,112)]. These proteins are found in an underphosphorylated active state during G_0 and early G_1 phases; but as cells pass the restriction point in mid to late G_1 phase, the pocket proteins are inactivated through hyperphosphorylation by the cyclin D- and cyclin E-dependent kinases (32,35,82,85,112). For much of the mammalian cell cycle, there is an inverse correlation between the activity of the pocket proteins and the level of pol III transcription. Thus, expression of class III genes is low during G_0 and early G_1 phases and then increases at the G_1/S transition (48,79,128). Recent data suggest that the pocket proteins play a major role in the cell cycle control of pol III transcription.

Whereas TFIIC activity remains relatively constant in cycling mammalian cells, TFIIB is regulated strongly (128,129). As a consequence, the limiting component of the pol III machinery changes as cells cycle. During mitosis and early G_1 phase, the activity of TFIIB is severely limiting, but it increases sub-

stantially at the G_1/S transition and is in relative excess throughout S and G_2 (128,129). Detailed time courses show that the rise in pol III transcription occurs in mid to late G_1 phase and corresponds well with the time when RB and its relatives are switched off by hyperphosphorylation [(48,79), P. Scott and R. White, unpublished data]. Coimmunoprecipitation experiments confirm that the pocket proteins dissociate from TFIIB when cells enter S phase (Fig. 1). Indeed, TFIIB is bound exclusively by the underphosphorylated active form of RB and not by the hyperphosphorylated forms found after the G_1/S transition (J. Sutcliffe and R. White, unpublished data). Consistent with these observations, pol III transcription is stimulated strongly if cells are transfected with vectors encoding cyclin D/cdk4 and cyclin E/cdk2, the kinases responsible for phosphorylating the pocket proteins (C. Cairns and R. White, unpublished data). Having been switched off at the restriction point, RB and its relatives remain inactive until they are dephosphorylated at the start of the next G_1 phase (32,35,82,112).

Figure 1. RB binds to TFIIB during G_0 and early G_1 phase, but is released as cells pass through the G_1/S transition. The graph compares the level of interaction between RB and TFIIB in Balb/c 3T3 cells harvested in G_0 , mid- G_1 , or S phase, as indicated. Arrest in G_0 phase was achieved by serum deprivation for 24 h; 20% serum was then added and cells were harvested after 9 h (mid- G_1 phase) or 15 h (S phase). Cell cycle phase was confirmed by flow cytometry and by measuring thymidine incorporation. Protein was extracted from the harvested cells and used for immunoprecipitation with the anti-RB antibody C15 (Santa Cruz), as described previously (110). The amounts of RB and associated TFIIB in the immunoprecipitates were determined by scanning Western blots carried out with C15 and the anti-BRF antibody 128 (10). The amount of BRF in each immunoprecipitate was normalized against the total amount of RB in the same immunoprecipitate. Numbers represent percentages of the interaction seen in G_0 phase (designated 100%).

The activity of TFIIB and the expression of class III genes is maximal during S and G₂ phases (128). However, this situation is rapidly reversed once mitosis is reached. Indeed, mitosis in higher eukaryotes is accompanied by a general decrease in transcription by all three nuclear RNA polymerases [reviewed in (29)]. In the case of pol III, this is achieved through the phosphorylation and inactivation of TFIIB (31,73,129). Thus, TFIIB isolated from metaphase-arrested frog eggs is unable to support transcription unless it is treated with phosphatase (31). The mitotic kinase cyclin B/cdk2 is at least partially responsible for this effect, because it can inactivate affinity-purified *Xenopus* TFIIB (31,136). It is striking that the cyclin-dependent kinases have opposite effects on the class III system at different stages of the cell cycle; pol III activity increases during G₁ phase in response to cyclin D/cdk4 and cyclin E/cdk2, but in M phase it is repressed by cyclin B/cdk2. However, there is redundancy in the mechanism of mitotic control and one or more additional kinases can also repress pol III transcription in metaphase-arrested frog eggs (33). A similar situation is found in mitotic HeLa cells, where TFIIB is also inactivated in a phosphorylation-dependent manner (129). In both the frog and human systems, TBP is found in a hyperphosphorylated state during mitosis (73,129). However, the functional significance of this remains unclear and repression of pol III transcription appears to be due to a specific loss of activity of one or more of the TAF subunits of TFIIB (73,129).

The hyperphosphorylation of TFIIB is reversed

soon after cycling human cells leave mitosis (128). Despite this, TFIIB activity remains low during early G₁ phase (128). As a consequence, the level of pol III transcription is two- to threefold lower in early G₁ than it is in S and G₂ phases (128). This repression coincides with the interval during which the pocket proteins are active, following their dephosphorylation at the end of mitosis (82). They bind to TFIIB and inhibit it until the restriction point is reached in mid to late G₁ phase (Fig. 2).

In addition to their window of action during early G₁, the pocket proteins are also underphosphorylated and active in quiescent cells (32,35). Indeed, the abundance of p130 is especially elevated in serum-starved resting cells (32,35,45,80). It is likely that hypophosphorylated p130 and RB play an important part in suppressing pol III transcription during G₀ phase. Thus, TFIIB is bound by p130 and RB in quiescent fibroblasts (P. Scott and R. White, unpublished data). Furthermore, cells derived from *Rb*^{-/-} knockout or *p107*^{-/-} *p130*^{-/-} double knockout mice are compromised in their ability to downregulate pol III activity following serum withdrawal [(110), P. Scott and R. White, unpublished data]. These observations suggest that the pocket proteins make a major contribution towards the serum responsiveness of class III genes.

As well as using RB and p130 to repress TFIIB, some mammalian cell types may also inactivate TFIIC2 when they are deprived of mitogens (11,37,115). In HeLa cells, regulation of TFIIC2 appears to be achieved by interconversion between two

Figure 2. Model illustrating changes in the pol III transcription machinery in cycling mammalian cells. During early G₁ phase, TFIIB is bound and repressed by RB. At the G₁/S transition, RB dissociates from TFIIB, allowing active transcription throughout S and G₂ phases. At mitosis, TFIIB is inactivated through hyperphosphorylation, resulting in a drop in transcription. Although TFIIB has been depicted as remaining at the promoter throughout the cell cycle, it is possible that it dissociates in response to RB binding and/or mitotic phosphorylation.

forms: TFIIC2a, which is active, and TFIIC2b, which is transcriptionally inactive although still able to bind DNA (37,59,107). The inactive TFIIC2b form is reported to lack a 110-kDa subunit called TFIIC β (59,107). Both forms are present in logarithmically growing HeLa cells, but low serum levels trigger a specific decrease in the abundance of TFIIC β so that the inactive form predominates (107). Thus, both TFIIB and TFIIC2 can respond to the availability of mitogens. The relative importance of these two regulatory mechanisms will probably depend upon cell type. We observe no change in TFIIC β levels when Balb/c 3T3 fibroblasts are deprived of serum (H. Alzuherri, A. Winter, and R. White, unpublished data).

VIRUSES

A variety of viruses have been found to stimulate pol III transcription [reviewed in (126)]. In many cases this seems to reflect a general requirement for increased biosynthetic capacity, but several viral genomes contain class III genes. For example, adenovirus encodes two pol III products, called VA_I and VA_{II}, that are synthesized at high levels during the late stages of infection (108,124). These short RNAs are involved in subverting the host cells translational apparatus, in order to ensure the synthesis of viral proteins (114). Multiple mechanisms may contribute to the activation of pol III transcription in response to adenovirus infection. HeLa cells infected with wild-type adenovirus display a marked increase in TFIIC2 activity (37,38,107,138). This reflects a selective increase in the level of the TFIIC β subunit, thereby raising the proportion of the active TFIIC2a form (37,107). The adenoviral transforming protein E1A is required for induction of TFIIC β (37,107). E1A also binds and inactivates the pocket proteins, allowing it to relieve TFIIB from repression by RB (132). In addition, E1A can counteract the effects of another cellular repressor called Dr1 (62). Because Dr1 is a potent inhibitor of TFIIB, both in vitro and in vivo (57,130), this may provide an additional route for adenovirus to ensure high levels of pol III activity.

Rodent fibroblasts display elevated levels of pol III transcripts following transformation by the DNA tumor virus SV40 (12,102,106,131). The mechanisms used to achieve this bear several similarities to those employed by adenovirus. For example, the large transforming (T) antigen of SV40 resembles E1A in being able to bind and inactivate RB (22,26,76,84). This allows large T antigen to release TFIIB from the repressive influence of RB (70). The proportion of TFIIB bound by RB is significantly reduced in

SV40-transformed fibroblasts and this correlates with an increase in TFIIB activity (70). Large T antigen has also been reported to bind to TFIIB, although the functional significance of this interaction has yet to be established (20). In addition to activating TFIIB, SV40-transformed fibroblasts also overexpress TFIIC2, which is the limiting factor for pol III transcription in these cells (70,131). Like adenovirus, SV40 induces a substantial increase in the level of TFIIC β (70). However, SV40-transformed fibroblasts also overproduce other subunits of TFIIC2 (70), which is apparently not the case in adenovirus-infected HeLa cells (107). The elevated levels of TFIIC2 subunits that follow transformation by SV40 reflect an overproduction of the corresponding mRNAs (70). For example, the two SV40-transformed lines that were tested express seven- to eight-fold more of the mRNA encoding TFIIC β than the corresponding untransformed parental cells (70). Thus, SV40 resembles adenovirus in deregulating both TFIIB and TFIIC2 in order to achieve very high levels of pol III output (Fig. 3).

Other viruses may be more selective in their choice of targets within the class III transcription machinery. For example, hepatitis B virus (HBV) induces a specific increase in TFIIB activity (120). This effect is associated with the viral X gene, which alone is sufficient to stimulate pol III transcription when introduced into a variety of cell lines (2,64,119,120). The X gene provokes a substantial increase in the abundance of TBP, a key component of the TFIIB complex (119,120). This X-induced overexpression of TBP may be sufficient to account for the higher TFIIB activity, because TBP is limiting for pol III transcription in the cell lines used in these studies (117,120). The X gene products have been shown to stimulate the protein kinase C (PKC) and Ras-Raf-MEK-MAP kinase signaling cascades (6,53) and both these pathways have been implicated in the effect of X on pol III transcription (119,120). Thus, inhibitors of either PKC or Ras can block the X-mediated increase in TBP abundance and class III gene expression (119,120). This can also be achieved with a dominant negative mutant form of Ras (119). Coexpression of constitutively active Raf-1 overcomes the block imposed by dominant negative Ras (119). It therefore appears that X stimulates pol III transcription via cellular signaling pathways.

A more direct effect on TFIIB is produced by the Tax protein of human T-cell leukemia virus type 1 (HTLV-1), which can increase the expression of pol III templates both in vitro and in transfected cells (30,89). TFIIB activity and the synthesis of tRNA and 5S rRNA are elevated in T cells that have been infected with HTLV-1 (30). Furthermore, in reconsti-

Figure 3. Model illustrating some changes in the pol III transcription machinery that occur when Balb/c 3T3 cells are transformed by SV40. Whereas RB binds and represses some of the TFIIIB in untransformed 3T3 cells, SV40 T antigen sequesters RB and releases active TFIIIB. The SV40-transformed cells also overexpress TFIIIC2. As a consequence of these changes, SV3T3 cells have higher pol III transcription levels than their untransformed 3T3 progenitors.

tuted assays recombinant Tax can raise the effective concentration of active TFIIIB molecules (30). The precise molecular details of this effect have yet to be established.

TRANSFORMATION

A great many studies have observed that the abundance of pol III transcripts is abnormally elevated in transformed and tumor cell lines (7,60,61,67,77,100,102). A broad range of transforming agents can produce this effect. Adenovirus, SV40, HBV, and HTLV-1 provide examples that have already been described above. Both HBV and HTLV-1 are important causative agents in human diseases; HBV is linked strongly with the development of hepatocellular carcinoma (56), while HTLV-1 causes adult T-cell leukemia and a neurodegenerative disease called tropical spastic paraparesis or HTLV-1-associated myelopathy (46,90). In addition to these and other tumor viruses, many chemical carcinogens have also been found to stimulate pol III activity when applied to cells. A tight causal link between pol III activation and transformation is suggested by the fact that two fibroblast lines transformed by temperature-sensitive

mutants of the SV40 large T antigen downregulate pol III transcription at the nonpermissive temperature while reverting to normal morphology and phenotype (102). The abundance of pol III transcripts varies substantially between different SV40-transformed lines and the highest levels correlate with progression to a more tumorigenic phenotype (102,131). However, a few rare examples have been reported of transformed lines that do not display the characteristic increase in pol III transcript levels, such as the *Rb^{+/+} p53^{+/+}* osteosarcoma cell line U2OS (132).

Almost all the work described above was carried out with cultured cells. However, two recent studies have demonstrated clearly that pol III is also consistently deregulated in tumors in vivo. The first of these examined a murine pol III transcript of unknown function called BC1, which is unusual because it is normally only expressed in neurons (23). Northern analysis showed BC1 expression in breast carcinomas, colonic adenocarcinomas, and skin fibrosarcomas, but not in the corresponding untransformed tissues (14). In situ hybridization studies of these tumors confirmed the presence of BC1 RNA in the neoplastic cells, whereas it was absent from the surrounding tissues (14). Although the fibrosarcomas and adenocarcinomas were induced by local inocula-

tion with cells that had been treated with chemical carcinogens, the breast carcinoma analyzed was a primary tumor caused by ras (14). A more extensive analysis has been carried out with samples from 80 human tumors, representing 19 different types of cancer; it found that BC200 RNA, the primate analogue of BC1, is expressed in many, but not all, primary human tumors (13). Like BC1, BC200 RNA is found exclusively in the malignant cells and not in the adjacent normal tissue (13). An even more striking observation to emerge from this study is that levels of 7SL RNA, an essential pol III product, were elevated in every tumor examined relative to the corresponding normal tissue (13). We have also found that ovarian carcinomas overexpress 7SL RNA, tRNA, and 5S rRNA, relative to healthy ovarian tissue from the same patients (A. Winter, G. Sourvinos, D. Spanidos, and R. White, unpublished data). Thus, abnormal activation of class III gene expression is a very frequent feature of tumors *in vivo*.

Although deregulation of pol III activity has been observed in a broad range of transformed cell types, in most cases the mechanistic basis of this effect has yet to be elucidated. However, a potential explanation is offered by the discovery that RB and p53 play a major role in repressing TFIIB in untransformed cells. The p53 gene contains missense mutations in approximately half of the major forms of human cancer (39). The effects of such mutations on pol III transcription have yet to be reported, but there is a good chance that many will release TFIIB from a constraining influence. Furthermore, wild-type p53 can be inactivated by the cellular oncoprotein Mdm2, which is overexpressed in certain tumor types, including 30–40% of human sarcomas (83). Mdm2 might therefore be expected to deregulate TFIIB. Although highly plausible, it has yet to be established experimentally that p53 inactivation contributes to the elevated pol III activity found in tumors. However, evidence has already been provided that this is the case for RB.

Many human cancers carry mutations in *Rb*, including retinoblastomas where the gene was first identified (27,123). In some instances the *Rb* gene is deleted completely; *Rb*^{-/-} mice provide a model for this situation and have allowed confirmation that pol III transcription is elevated *in vivo* when RB protein is missing (132). Many other tumors carry mutant forms of RB and in these cases the mutation generally incorporates the pocket domain (43). Deletion and substitution analyses have shown that the pocket domain is essential for RB to regulate pol III activity (16,132). Furthermore, TFIIB is unable to bind to a mutant form of RB that is found in the osteosarcoma cell line SAOS2 (70), where a C-terminal truncation

has removed part of the pocket (104). Several examples have been described in which highly localized mutations inactivate the pocket. For example, in one small-cell lung carcinoma a single base change in a splice acceptor site gave rise to an RB polypeptide that lacked the 35 amino acids encoded by exon 21 (40). In another small-cell lung carcinoma, a point mutation created a stop codon and a novel splice donor site within exon 22, thereby eliminating 38 residues from the pocket domain of the product (40). A third inactivating mutation from a small-cell lung cancer resulted in a single amino acid substitution at codon 706 (52). We tested the ability of each of these three naturally occurring mutants to regulate pol III transcription and found that repression was lost in every case (132). We have also examined the effect of a point mutation at residue 567 of RB, which was isolated from the germ line of a child with bilateral retinoblastoma (103). As shown in Figure 4, this single residue substitution is sufficient to prevent RB from repressing a pol III template following overexpression in transfected cells. This is clearly a limited survey, but it nevertheless demonstrates that mutations that arise in RB in tumors can compromise its ability to regulate pol III transcription.

Figure 4. A substitution in RB (567L) that arose in a retinoblastoma patient compromises its ability to repress pol III transcription. The graph shows levels of VA1 transcription by pol III in transfected SAOS2 cells, after normalization to a cotransfected pol II control (pCAT) containing the SV40 promoter. Cells received 4 μ g of pVA1, 4 μ g of pCAT, and 8 μ g of pSG5L vector, pSG5L-HA-RB(wt), or pSG-RB;567L (103), as indicated. RNA was harvested after 48 h and the levels of VA1 and CAT transcripts were determined by primer extension, as previously described (110). A phosphorimager was used for quantitation. Western blotting confirmed that wild-type and 567L mutant RB are expressed at comparable levels, as previously reported (103).

Although most cancers retain wild-type RB, its function is usually found to be compromised. Indeed, it has been suggested that the regulatory pathway involving RB may be disrupted in all human malignancies (123). A survey of seven human cervical carcinoma cell lines found that two had sustained small inactivating mutations in RB (101). Whereas neither of these lines were infected by human papillomavirus (HPV), each of the remaining five lines that expressed wild-type RB also carried HPV DNA (101). HPVs have an etiologic role in most cervical malignancies (118). The viral gene product E7 that is expressed in these tumors binds to the pocket domain of RB and inactivates it (25,86). Thus, RB function may be lost in most if not all cervical cancers, either by gene mutation in the minority of HPV-negative cases or by complex formation with E7 oncoprotein (118). We have shown that pol III transcription can be strongly stimulated *in vivo* by the E7 product of the highly malignant strain HPV-16 (70,110). This is not an indirect response to cell transformation, because pol III is also activated by a nontransforming mutant version of E7 that has retained its ability to inactivate RB (70). However, deletions or substitutions in the pocket-binding domain of E7 abolish its capacity to stimulate expression of a class III gene (70,110). It is therefore highly likely that E7 deregulates pol III transcription by releasing TFIIB from repression by RB and its relatives p107 and p130.

The oncoproteins of several other DNA tumor viruses can also bind RB and neutralize its function, including adenoviral E1A (133,134) and SV40 large T antigen (22,84). As already described, both E1A and large T can overcome the repression of pol III activity by RB (70,132). Furthermore, the interaction between RB and TFIIB is diminished substantially in SV40-transformed cells (70). Release of TFIIB from the inhibitory effects of the pocket proteins is therefore a feature of cells transformed by various DNA tumor viruses.

As already described, the activity of RB can also be switched off through phosphorylation by the cyclin D- and E-dependent kinases. Cyclin D-dependent kinases are hyperactive in a variety of cancers and this provides another mechanism whereby RB function is lost (4,44,123). For example, cyclin D1 is overexpressed in 30–40% of primary breast tumors (4). In addition to situations in which cyclins are affected directly, many other cancers have lost the function of p16, a specific repressor of the cyclin D-dependent kinases (36,44). For example, the gene for p16 is deleted in many oesophageal, bladder, lung, and pancreatic carcinomas (36). Thus, cyclin D-dependent kinase activity is abnormally elevated in a broad spectrum of cancers, which has the effect of

switching off RB. As might have been predicted, pol III transcription is stimulated strongly when various cell types are transfected with vectors encoding cyclin D and cdk4 (C. Cairns and R. White, unpublished data). To mimic the effect of p16 deletion, we have made use of a ribozyme that degrades the p16 mRNA (88); pol III transcription is elevated significantly when this approach is used to deplete p16 from cells (P. Scott and R. White, unpublished data). Thus, aberrant pol III activity can result when RB function is compromised through genetic mutation, hyperphosphorylation, or binding of viral oncoproteins. Because one or another of these mechanisms is thought to apply to the vast majority of tumors (123), these observations are likely to go a long way towards explaining the very high incidence of pol III deregulation in human cancers.

RAPID GROWTH REQUIRES HIGH RATES OF POL III TRANSCRIPTION

That TFIIB is targeted by cellular tumor suppressors and a range of viral oncoproteins can be explained by the fact that pol III transcriptional activity is tightly linked to the rate of growth. To maintain a constant size, cells must double their mass prior to division. Because protein constitutes the bulk of a cell's dry mass, a high rate of translation is a prerequisite of rapid growth. Indeed, growth rate is directly proportional to the rate of accumulation of protein (5). A 50% decrease in the level of protein synthesis causes cells to withdraw from cycle and quiesce (8,96). An important determinant of the rate of translation is the availability of rRNA and tRNA. High pol III activity is therefore necessary to sustain rapid growth. Thus, mitogenic stimulation provokes a rapid and coordinate induction of rRNA, tRNA, ribosomal proteins, and translation factors, such that the rate of protein synthesis increases substantially before cells reach S phase (17,48,54,79,93,97,98,109,111). Indeed, cells are unable to enter S phase and duplicate their chromosomes until they have accumulated an adequate level of protein (55,113). These observations can readily explain why pol III transcription is targeted by so many viruses that need the host cell's DNA synthesis machinery to replicate their genomes. It may also account, at least in part, for the frequent activation of pol III transcription in transformed and tumor cells.

CONCLUSION

TFIIB is a target for many regulatory proteins, including several viral oncoproteins and the tumor

suppressors p53 and RB. It is also subject to mitotic repression through direct phosphorylation. These observations suggest strongly that TFIIB is a crucial cellular control point. The activity of TFIIB is clearly a major determinant of biosynthetic capacity, dictating the rate of production of tRNA, 5S rRNA, and several other essential small RNA molecules. It has been suggested that the repression of pol III transcription may provide a mechanism for restraining cell growth (68,87,125). The fact that this process is targeted by two unrelated tumor suppressors and a range of viral oncoproteins provides support for this contention. It seems very likely that the loss of function of p53 and/or RB will deregulate pol III transcription in a large proportion of malignancies. This

may constitute an important step towards tumor development.

ACKNOWLEDGMENTS

The authors thank William Kaelin, Jr., for the pSG5L, pSG5L-HA-RB(wt), and pSG-RB;567L plasmids. Our research is supported by project grants CO5766 and 17/C10311 from the Biotechnology and Biological Sciences Research Council, SP2314/0102 from the Cancer Research Campaign, and 98-46 from the Association for International Cancer Research. P.H.S. is a Wellcome Trust Research Career Development Fellow and R.J.W. is a Jenner Research Fellow of the Lister Institute of Preventive Medicine.

REFERENCES

1. Aasland, R.; Stewart, A. F.; Gibson, T. The SANT domain: A putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional corepressor N-CoR and TFIIB. *Trends Biochem. Sci.* 21: 87–88; 1996.
2. Aufiero, B.; Schneider, R. J. The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters. *EMBO J.* 9:497–504; 1990.
3. Bartholomew, B.; Kassavetis, G. A.; Geiduschek, E. P. Two components of *Saccharomyces cerevisiae* transcription factor IIIB (TFIIB) are stereospecifically located upstream of a tRNA gene and interact with the second-largest subunit of TFIIC. *Mol. Cell. Biol.* 11:5181–5189; 1991.
4. Bates, S.; Peters, G. Cyclin D1 as a cellular proto-oncogene. *Semin. Cancer Biol.* 6:73–82; 1995.
5. Baxter, G. C.; Stanners, C. P. The effect of protein degradation on cellular growth characteristics. *J. Cell Physiol.* 96:139–146; 1978.
6. Bann, J.; Schneider, R. J. Hepatitis B virus HBx protein activates Ras–GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. *Proc. Natl. Acad. Sci. USA* 91:10350–10354; 1990.
7. Brickell, P. M.; Latchman, D. S.; Murphy, D.; Wilison, K.; Rigby, P. W. J. Activation of a *Qa/Tla* class I major histocompatibility antigen gene is a general feature of oncogenesis in the mouse. *Nature* 306:756–760; 1983.
8. Brooks, R. F. Continuous protein synthesis is required to maintain the probability of entry into S phase. *Cell* 12:311–317; 1977.
9. Buratowski, S.; Zhou, H. A suppressor of TBP mutations encodes an RNA polymerase III transcription factor with homology to TFIIB. *Cell* 71:221–230; 1992.
10. Cairns, C. A.; White, R. J. p53 is a general repressor of RNA polymerase III transcription. *EMBO J.* 17: 3112–3123; 1998.
11. Carey, M. F.; Singh, K. Enhanced B2 transcription in simian virus 40-transformed cells is mediated through the formation of RNA polymerase III transcription complexes on previously inactive genes. *Proc. Natl. Acad. Sci. USA* 85:7059–7063; 1988.
12. Carey, M. F.; Singh, K.; Botchan, M.; Cozzarelli, N. R. Induction of specific transcription by RNA polymerase III in transformed cells. *Mol. Cell. Biol.* 6: 3068–3076; 1986.
13. Chen, W.; Bocker, W.; Brosius, J.; Tiedge, H. Expression of neural BC200 RNA in human tumours. *J. Pathol.* 183:345–351; 1997.
14. Chen, W.; Heierhorst, J.; Brosius, J.; Tiedge, H. Expression of neural *BCI* RNA: Induction in murine tumours. *Eur. J. Cancer* 33:288–292; 1997.
15. Chesnokov, I.; Chu, W.-M.; Botchan, M. R.; Schmid, C. W. p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner. *Mol. Cell. Biol.* 16:7084–7088; 1996.
16. Chu, W.-M.; Wang, Z.; Roeder, R. G.; Schmid, C. W. RNA polymerase III transcription repressed by Rb through its interactions with TFIIB and TFIIC2. *J. Biol. Chem.* 272:14755–14761; 1997.
17. Clarke, E. M.; Peterson, C. L.; Brainard, A. V.; Riggs, D. L. Regulation of the RNA polymerase I and III transcription systems in response to growth conditions. *J. Biol. Chem.* 271:22189–22195; 1996.
18. Claudio, P. P.; Howard, C. M.; Baldi, A.; De Luca, A.; Fu, Y.; Condorelli, G.; Sun, Y.; Colburn, N.; Calabretta, B.; Giordano, A. p130/Rb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. *Cancer Res.* 54:5556–5560; 1994.
19. Colbert, T.; Hahn, S. A yeast TFIIB-related factor involved in RNA polymerase III transcription. *Genes Dev.* 6:1940–1949; 1992.
20. Damania, B.; Mital, R.; Alwine, J. C. Simian virus 40 large T antigen interacts with human TFIIB-related factor and small nuclear RNA-activating protein complex for transcriptional activation of TATA-containing polymerase III promoters. *Mol. Cell. Biol.* 18: 1331–1338; 1998.

21. Dean, N.; Berk, A. J. Ordering promoter binding of class III transcription factors TFIIC1 and TFIIC2. *Mol. Cell. Biol.* 8:3017–3025; 1988.
22. DeCaprio, J. A.; Ludlow, J. W.; Figge, J.; Shew, J.-Y.; Huang, C.-M.; Lee, W.-H.; Marsilio, E.; Paucha, E.; Livingston, D. M. SV40 large tumour antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. *Cell* 54:275–283; 1988.
23. DeChiara, T. M.; Brosius, J. Neural BC1 RNA: cDNA clones reveal nonrepetitive sequence content. *Proc. Natl. Acad. Sci. USA* 84:2624–2628; 1987.
24. Dyson, N. The regulation of E2F by pRB-family proteins. *Genes Dev.* 12:2245–2262; 1998.
25. Dyson, N.; Howley, P. M.; Munger, K.; Harlow, E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science* 243:934–937; 1989.
26. Ewen, M. E.; Ludlow, J. W.; Marsilio, E.; DeCaprio, J. A.; Millikan, R. C.; Cheng, S. H.; Paucha, E.; Livingston, D. M. An N-terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110^{Rb} and a second cellular protein, p120. *Cell* 58:257–267; 1989.
27. Friend, S. H.; Bernards, R.; Rogelj, S.; Weinberg, R. A.; Rapaport, J. M.; Alberts, D. M.; Dryja, T. P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 323:643–646; 1986.
28. Giaccia, A. J.; Kastan, M. B. The complexity of p53 modulation: Emerging patterns from divergent signals. *Genes Dev.* 12:2973–2983; 1998.
29. Gottesfeld, J. M.; Forbes, D. J. Mitotic repression of the transcriptional machinery. *Trends Biochem. Sci.* 22:197–202; 1997.
30. Gottesfeld, J. M.; Johnson, D. L.; Nyborg, J. K. Transcriptional activation of RNA polymerase III-dependent genes by the human T-cell leukaemia virus type 1 Tax protein. *Mol. Cell. Biol.* 16:1777–1785; 1996.
31. Gottesfeld, J. M.; Wolf, V. J.; Dang, T.; Forbes, D. J.; Hartl, P. Mitotic repression of RNA polymerase III transcription in vitro mediated by phosphorylation of a TFIIB component. *Science* 263:81–84; 1994.
32. Grana, X.; Garriga, J.; Mayol, X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. *Oncogene* 17:3365–3383; 1998.
33. Hartl, P.; Gottesfeld, J.; Forbes, D. J. Mitotic repression of transcription in vitro. *J. Cell Biol.* 120:613–624; 1993.
34. Hernandez, N. TBP, a universal eukaryotic transcription factor? *Genes Dev.* 7:1291–1308; 1993.
35. Herwig, S.; Strauss, M. The retinoblastoma protein: A master regulator of cell cycle, differentiation and apoptosis. *Eur. J. Biochem.* 246:581–601; 1997.
36. Hiram, T.; Koeffler, H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. *Blood* 86:841–854; 1995.
37. Hoeffler, W. K.; Kovelman, R.; Roeder, R. G. Activation of transcription factor IIIC by the adenovirus E1A protein. *Cell* 53:907–920; 1988.
38. Hoeffler, W. K.; Roeder, R. G. Enhancement of RNA polymerase III transcription by the E1A gene product of adenovirus. *Cell* 41:955–963; 1985.
39. Hollstein, M.; Rice, K.; Greenblatt, M. S.; Soussi, T.; Fucks, R.; Sorlie, T.; Hovig, E.; Smith-Sorensen, B.; Montesano, R.; Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. *Nucleic Acids Res.* 22:3551–3555; 1994.
40. Horowitz, J. M.; Park, S.-H.; Bogenmann, E.; Cheng, J.-C.; Yandell, D. W.; Kaye, F. J.; Minna, J. D.; Dryja, T. P.; Weinberg, R. A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumour cells. *Proc. Natl. Acad. Sci. USA* 87:2775–2779; 1990.
41. Hsieh, Y.-J.; Kundu, T. K.; Wang, Z.; Kovelman, R.; Roeder, R. G. The TFIIC90 subunit of TFIIC interacts with multiple components of the RNA polymerase III machinery and contains a histone-specific acetyltransferase activity. *Mol. Cell. Biol.* 19:7697–7704; 1999.
42. Hsieh, Y.-J.; Wang, Z.; Kovelman, R.; Roeder, R. G. Cloning and characterization of two evolutionarily conserved subunits (TFIIC102 and TFIIC63) of human TFIIC and their involvement in functional interactions with TFIIB and RNA polymerase III. *Mol. Cell. Biol.* 19:4944–4952; 1999.
43. Hu, Q.; Dyson, N.; Harlow, E. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. *EMBO J.* 9:1147–1155; 1990.
44. Hunter, T.; Pines, J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. *Cell* 79:573–582; 1994.
45. Hurford, R. K.; Cobrinik, D.; Lee, M.-H.; Dyson, N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. *Genes Dev.* 11:1447–1463; 1997.
46. Jacobson, S.; Raine, C. S.; Mingioli, E. S.; McFarlin, D. E. Isolation of an HTLV-I-like retrovirus from patients with tropical spastic paraparesis. *Nature* 331:540–543; 1988.
47. Joazeiro, C. A. P.; Kassavetis, G. A.; Geiduschek, E. P. Identical components of yeast transcription factor IIIB are required and sufficient for transcription of TATA box-containing and TATA-less genes. *Mol. Cell. Biol.* 14:2798–2808; 1994.
48. Johnson, L. F.; Abelson, H. T.; Green, H.; Penman, S. Changes in RNA in relation to growth of the fibroblast. I. Amounts of mRNA, rRNA, and tRNA in resting and growing cells. *Cell* 1:95–100; 1974.
49. Kassavetis, G. A.; Braun, B. R.; Nguyen, L. H.; Geiduschek, E. P. *S. cerevisiae* TFIIB is the transcription initiation factor proper of RNA polymerase III, while TFIIA and TFIIC are assembly factors. *Cell* 60:235–245; 1990.
50. Kassavetis, G. A.; Joazeiro, C. A. P.; Pisano, M.; Geiduschek, E. P.; Colbert, T.; Hahn, S.; Blanco, J. A. The role of the TATA-binding protein in the assem-

- bly and function of the multisubunit yeast RNA polymerase III transcription factor, TFIIB. *Cell* 71:1055–1064; 1992.
51. Kassavetis, G. A.; Nguyen, S. T.; Kobayashi, R.; Kumar, A.; Geiduschek, E. P.; Pisano, M. Cloning, expression, and function of *TFC5*, the gene encoding the B'' component of the *Saccharomyces cerevisiae* RNA polymerase III transcription factor TFIIB. *Proc. Natl. Acad. Sci. USA* 92:9786–9790; 1995.
 52. Kaye, F. J.; Kratzke, R. A.; Gerster, J. L.; Horowitz, J. M. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. *Proc. Natl. Acad. Sci. USA* 87:6922–6926; 1990.
 53. Kekule, A. S.; Lauer, U.; Weiss, L.; Lubner, B.; Hofschneider, P. H. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. *Nature* 361:742–745; 1993.
 54. Kief, D. R.; Warner, J. R. Coordinate control of syntheses of ribosomal ribonucleic acid and ribosomal proteins during nutritional shift-up in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 1:1007–1015; 1981.
 55. Killander, D.; Zetterberg, A. A quantitative cytochemical investigation of the relationship between cell mass and initiation of DNA synthesis in mouse fibroblasts *in vitro*. *Exp. Cell Res.* 40:12–20; 1965.
 56. Kim, C.-M.; Koike, K.; Saito, I.; Miyamura, T.; Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. *Nature* 351:317–320; 1991.
 57. Kim, S.; Na, J. G.; Hampsey, M.; Reinberg, D. The Dr1/DRAP1 heterodimer is a global repressor of transcription *in vivo*. *Proc. Natl. Acad. Sci. USA* 94:820–825; 1997.
 58. Ko, L. J.; Prives, C. p53: Puzzle and paradigm. *Genes Dev.* 10:1054–1072; 1996.
 59. Kovelman, R.; Roeder, R. G. Purification and characterization of two forms of human transcription factor IIIC. *J. Biol. Chem.* 267:24446–24456; 1992.
 60. Kramerov, D. A.; Lekakh, I. V.; Samarina, O. P.; Ryskov, A. P. The sequences homologous to major interspersed repeats B1 and B2 of mouse genome are present in mRNA and cytoplasmic poly(A)⁺ RNA. *Nucleic Acids Res.* 10:7477–7491; 1982.
 61. Kramerov, D. A.; Tillib, S. V.; Shumyatsky, G. P.; Georgiev, G. P. The most abundant nascent poly(A)⁺ RNAs are transcribed by RNA polymerase III in murine tumor cells. *Nucleic Acids Res.* 18:4499–4506; 1990.
 62. Kraus, V. B.; Inostroza, J. A.; Yeung, K.; Reinberg, D.; Nevins, J. R. Interaction of the Dr1 inhibitory factor with the TATA binding protein is disrupted by adenovirus E1A. *Proc. Natl. Acad. Sci. USA* 91:6279–6282; 1994.
 63. Kundu, T. K.; Wang, Z.; Roeder, R. G. Human TFIIC relieves chromatin-mediated repression of RNA polymerase III transcription and contains an intrinsic histone acetyltransferase activity. *Mol. Cell. Biol.* 19:1605–1615; 1999.
 64. Kwee, L.; Lucito, R.; Aufiero, B.; Schneider, R. J. Alternate translation initiation on hepatitis B virus X mRNA produces multiple polypeptides that differentially transactivate class II and III promoters. *J. Virol.* 66:4382–4389; 1992.
 65. L'Etoile, N. D.; Fahnestock, M. L.; Shen, Y.; Aebersold, R.; Berk, A. J. Human transcription factor IIIC box B binding subunit. *Proc. Natl. Acad. Sci. USA* 91:1652–1656; 1994.
 66. Lagna, G.; Kovelman, R.; Sukegawa, J.; Roeder, R. G. Cloning and characterization of an evolutionarily divergent DNA-binding subunit of mammalian TFIIC. *Mol. Cell. Biol.* 14:3053–3064; 1994.
 67. Lania, L.; Pannuti, A.; La Mantia, G.; Basilico, C. The transcription of B2 repeated sequences is regulated during the transition from quiescent to proliferative state in cultured rodent cells. *FEBS Lett.* 219:400–404; 1987.
 68. Larminie, C. G. C.; Alzuherri, H. M.; Cairns, C. A.; McLees, A.; White, R. J. Transcription by RNA polymerases I and III: A potential link between cell growth, protein synthesis and the retinoblastoma protein. *J. Mol. Med.* 76:94–103; 1998.
 69. Larminie, C. G. C.; Cairns, C. A.; Mital, R.; Martin, K.; Kouzarides, T.; Jackson, S. P.; White, R. J. Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein. *EMBO J.* 16:2061–2071; 1997.
 70. Larminie, C. G. C.; Sutcliffe, J. E.; Tosh, K.; Winter, A. G.; Felton-Edkins, Z. A.; White, R. J. Activation of RNA polymerase III transcription in cells transformed by simian virus 40. *Mol. Cell. Biol.* 19:4927–4934; 1999.
 71. Larminie, C. G. C.; White, R. J. Identification of a putative BRF homologue in the genome of *Caenorhabditis elegans*. *DNA Sequence* 9:49–58; 1998.
 72. Lassar, A. B.; Martin, P. L.; Roeder, R. G. Transcription of class III genes: Formation of preinitiation complexes. *Science* 222:740–748; 1983.
 73. Leresche, A.; Wolf, V. J.; Gottesfeld, J. M. Repression of RNA polymerase II and III transcription during M phase of the cell cycle. *Exp. Cell Res.* 229:282–288; 1996.
 74. Lobo, S. M.; Lister, J.; Sullivan, M. L.; Hernandez, N. The cloned RNA polymerase II transcription factor IID selects RNA polymerase III to transcribe the human U6 gene *in vitro*. *Genes Dev.* 5:1477–1489; 1991.
 75. Lopez-de-Leon, A.; Librizzi, M.; Tuglia, K.; Willis, I. PCF4 encodes an RNA polymerase III transcription factor with homology to TFIIB. *Cell* 71:211–220; 1992.
 76. Ludlow, J. W.; DeCaprio, J. A.; Huang, C.-M.; Lee, W.-H.; Paucha, E.; Livingston, D. M. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. *Cell* 56:57–65; 1989.
 77. Majello, B.; La Mantia, G.; Simeone, A.; Boncinelli, E.; Lania, L. Activation of major histocompatibility complex class I mRNA containing an *Alu*-like repeat in polyoma virus-transformed rat cells. *Nature* 314:457–459; 1985.

78. Margottin, F.; Dujardin, G.; Gerard, M.; Egly, J. M.; Huet, J.; Sentenac, A. Participation of the TATA factor in transcription of the yeast U6 gene by RNA polymerase C. *Science* 251:424–426; 1991.
79. Mauck, J. C.; Green, H. Regulation of pre-transfer RNA synthesis during transition from resting to growing state. *Cell* 3:171–177; 1974.
80. Mayol, X.; Garriga, J.; Grana, X. The transition from G₁ to G₀ involves G₁ cyclin/cdk-independent phosphorylation of p130 and its association with E2F-4. *Oncogene* 13:237–246; 1996.
81. Mital, R.; Kobayashi, R.; Hernandez, N. RNA polymerase III transcription from the human U6 and adenovirus type 2 VAI promoters has different requirements for human BRF, a subunit of human TFIIB. *Mol. Cell. Biol.* 16:7031–7042; 1996.
82. Mitnacht, S. Control of pRB phosphorylation. *Curr. Opin. Genet. Dev.* 8:21–27; 1998.
83. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The *MDM2* gene amplification database. *Nucleic Acids Res.* 26:3453–3459; 1998.
84. Moran, E. A region of SV40 large T antigen can substitute for a transforming domain of the adenovirus E1A products. *Nature* 334:168–170; 1988.
85. Mulligan, G.; Jacks, T. The retinoblastoma gene family: Cousins with overlapping interests. *Trends Genet.* 14:223–229; 1998.
86. Munger, K.; Werness, B. A.; Dyson, N.; Phelps, W. C.; Harlow, E.; Howley, P. M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour suppressor gene product. *EMBO J.* 8:4099–4105; 1989.
87. Nasmyth, K. Another role rolls in. *Nature* 382:28–29; 1996.
88. Nylandsted, J.; Rohde, M.; Bartek, J.; Strauss, M. Expression of a p16^{INK4a}-specific ribozyme downmodulates p16^{INK4a} abundance and accelerates cell proliferation. *FEBS Lett.* 436:41–45; 1998.
89. Piras, G.; Dittmer, J.; Radonovich, M. F.; Brady, J. N. Human T-cell leukaemia virus type I Tax protein transactivates RNA polymerase III promoter *in vitro* and *in vivo*. *J. Biol. Chem.* 271:20501–20506; 1996.
90. Poesz, B. J.; Ruscetti, F. W.; Gazdar, A. F.; Bunn, P. A.; Minna, J. D.; Gallo, R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 77:7415–7419; 1980.
91. Pombo, A.; Jackson, D. A.; Hollinshead, M.; Wang, Z.; Roeder, R. G.; Cook, P. R. Regional specialization in human nuclei: Visualization of discrete sites of transcription by RNA polymerase III. *EMBO J.* 18:2241–2253; 1999.
92. Qin, X.; Chittenden, T.; Livingston, D. M.; Kaelin, W. G. Identification of a growth suppression domain within the retinoblastoma gene product. *Genes Dev.* 6:953–964; 1992.
93. Redpath, N. T.; Proud, C. G. Molecular mechanisms in the control of translation by hormones and growth factors. *Biochim. Biophys. Acta* 1220:147–162; 1994.
94. Rigby, P. W. J. Three in one and one in three: It all depends on TBP. *Cell* 72:7–10; 1993.
95. Roberts, S.; Miller, S. J.; Lane, W. S.; Lee, S.; Hahn, S. Cloning and functional characterization of the gene encoding the TFIIB90 subunit of RNA polymerase III transcription factor TFIIB. *J. Biol. Chem.* 271:14903–14909; 1996.
96. Ronning, O. W.; Lindmo, T.; Pettersen, E. O.; Seglen, P. O. The role of protein accumulation in the cell cycle control of human NHK 3035 cells. *J. Cell. Physiol.* 109:411–418; 1981.
97. Rosenwald, I. B. Deregulation of protein synthesis as a mechanism of neoplastic transformation. *Bioessays* 18:243–250; 1996.
98. Rosenwald, I. B. Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2 α in transformed cells. *Cancer Lett.* 102:113–123; 1996.
99. Ruth, J.; Conesa, C.; Dieci, G.; Lefebvre, O.; Dusterhoft, A.; Ottonello, S.; Sentenac, A. A suppressor of mutations in the class III transcription system encodes a component of yeast TFIIB. *EMBO J.* 15:1941–1949; 1996.
100. Ryskov, A. P.; Ivanov, P. L.; Tokarskaya, O. N.; Kramerov, D. A.; Grigoryan, M. S.; Georgiev, G. P. Major transcripts containing B1 and B2 repetitive sequences in cytoplasmic poly(A)⁺ RNA from mouse tissues. *FEBS Lett.* 182:73–76; 1985.
101. Scheffner, M.; Munger, K.; Byrne, J. C.; Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. *Proc. Natl. Acad. Sci. USA* 88:5523–5527; 1991.
102. Scott, M. R. D.; Westphal, K.-H.; Rigby, P. W. J. Activation of mouse genes in transformed cells. *Cell* 34:557–567; 1983.
103. Sellers, W. R.; Novitch, B. G.; Miyake, S.; Heith, A.; Otterson, G. A.; Kaye, F. J.; Lassar, A. B.; Kaelin, W. G., Jr. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. *Genes Dev.* 12:95–106; 1998.
104. Shew, J.-Y.; Lin, B. T.-Y.; Chen, P.-L.; Tseng, B. Y.; Yang-Feng, T. L.; Lee, W.-H. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. *Proc. Natl. Acad. Sci. USA* 87:6–10; 1990.
105. Simmen, K. A.; Bernues, J.; Parry, H. D.; Stunnenberg, H. G.; Berkenstam, A.; Cavallini, B.; Egly, J. M.; Mattaj, I. W. TFIID is required for *in vitro* transcription of the human U6 gene by RNA polymerase III. *EMBO J.* 10:1853–1862; 1991.
106. Singh, K.; Carey, M.; Saragosti, S.; Botchan, M. Expression of enhanced levels of small RNA polymerase III transcripts encoded by the B2 repeats in simian virus 40-transformed mouse cells. *Nature* 314:553–556; 1985.
107. Sinn, E.; Wang, Z.; Kovelman, R.; Roeder, R. G. Cloning and characterization of a TFIIC2 subunit (TFIIC β) whose presence correlates with activation

- of RNA polymerase III-mediated transcription by adenovirus E1A expression and serum factors. *Genes Dev.* 9:675–685; 1995.
108. Soderlund, H.; Pettersson, U.; Vennstrom, B.; Philipson, L.; Mathews, M. B. A new species of virus-coded low molecular weight RNA from cells infected with adenovirus type 2. *Cell* 7:585–593; 1976.
 109. Stanners, C. P.; Adams, M. E.; Harkins, J. L.; Pollard, J. W. Transformed cells have lost control of ribosome number through their growth cycle. *J. Cell. Physiol.* 100:127–138; 1979.
 110. Sutcliffe, J. E.; Cairns, C. A.; McLees, A.; Allison, S. J.; Tosh, K.; White, R. J. RNA polymerase III transcription factor IIIB is a target for repression by pocket proteins p107 and p130. *Mol. Cell. Biol.* 19:4255–4261; 1999.
 111. Tatsuka, M.; Mitsui, H.; Wada, M.; Nagata, A.; Nojima, H.; Okayama, H. Elongation factor-1 α gene determines susceptibility to transformation. *Nature* 359:333–335; 1992.
 112. Taya, Y. RB kinases and RB-binding proteins: New points of view. *Trends Biochem. Sci.* 22:14–17; 1997.
 113. Terasima, T.; Yasukawa, M. Synthesis of G₁ protein preceding DNA synthesis in cultured mammalian cells. *Exp. Cell. Res.* 44:669; 1966.
 114. Thimmappaya, B.; Weinberger, C.; Schneider, R. J.; Shenk, T. Adenovirus VAI RNA is required for efficient translation of viral mRNA at late times after infection. *Cell* 31:543–551; 1982.
 115. Tower, J.; Sollner-Webb, B. Polymerase III transcription factor B activity is reduced in extracts of growth-restricted cells. *Mol. Cell. Biol.* 8:1001–1005; 1988.
 116. Trivedi, A.; Vilalta, A.; Gopalan, S.; Johnson, D. L. TATA-binding protein is limiting for both TATA-containing and TATA-lacking RNA polymerase III promoters in *Drosophila* cells. *Mol. Cell. Biol.* 16:6909–6916; 1996.
 117. Vilalta, A.; Trivedi, A.; Wang, Z.; Roeder, R. G.; Johnson, D. L. An RNA polymerase III-defective mutation in TATA-binding protein disrupts its interaction with a transcription factor IIIB subunit in *Drosophila* cells. *J. Biol. Chem.* 272:18087–18092; 1997.
 118. Vousden, K. H. Regulation of the cell cycle by viral oncoproteins. *Semin. Cancer Biol.* 6:109–116; 1995.
 119. Wang, H.-D.; Trivedi, A.; Johnson, D. L. Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signalling pathway. *Mol. Cell. Biol.* 17:6838–6846; 1997.
 120. Wang, H.-D.; Yuh, C.-H.; Dang, C. V.; Johnson, D. L. The hepatitis B virus X protein increases the cellular level of TATA-binding protein, which mediates transactivation of RNA polymerase III genes. *Mol. Cell. Biol.* 15:6720–6728; 1995.
 121. Wang, Z.; Roeder, R. G. Structure and function of a human transcription factor TFIIB subunit that is evolutionarily conserved and contains both TFIIB- and high-mobility-group protein 2-related domains. *Proc. Natl. Acad. Sci. USA* 92:7026–7030; 1995.
 122. Wang, Z.; Roeder, R. G. TFIIC1 acts through a downstream region to stabilize TFIIC2 binding to RNA polymerase III promoters. *Mol. Cell. Biol.* 16:6841–6850; 1996.
 123. Weinberg, R. A. The retinoblastoma protein and cell cycle control. *Cell* 81:323–330; 1995.
 124. Weinmann, R.; Raskas, H. J.; Roeder, R. G. Role of DNA-dependent RNA polymerases II and III in transcription of the adenovirus genome late in productive infection. *Proc. Natl. Acad. Sci. USA* 71:3426–3430; 1974.
 125. White, R. J. Regulation of RNA polymerases I and III by the retinoblastoma protein: A mechanism for growth control? *Trends Biochem. Sci.* 22:77–80; 1997.
 126. White, R. J. RNA polymerase III transcription. Berlin: Springer-Verlag; 1998.
 127. White, R. J. Transcription factor IIIB: An important determinant of biosynthetic capacity that is targeted by tumour suppressors and transforming proteins. *Int. J. Oncol.* 12:741–748; 1998.
 128. White, R. J.; Gottlieb, T. M.; Downes, C. S.; Jackson, S. P. Cell cycle regulation of RNA polymerase III transcription. *Mol. Cell. Biol.* 15:6653–6662; 1995.
 129. White, R. J.; Gottlieb, T. M.; Downes, C. S.; Jackson, S. P. Mitotic regulation of a TATA-binding-protein-containing complex. *Mol. Cell. Biol.* 15:1983–1992; 1995.
 130. White, R. J.; Khoo, B. C.-E.; Inostroza, J. A.; Reinberg, D.; Jackson, S. P. The TBP-binding repressor Dr1 differentially regulates RNA polymerases I, II and III. *Science* 266:448–450; 1994.
 131. White, R. J.; Stott, D.; Rigby, P. W. J. Regulation of RNA polymerase III transcription in response to Simian virus 40 transformation. *EMBO J.* 9:3713–3721; 1990.
 132. White, R. J.; Trouche, D.; Martin, K.; Jackson, S. P.; Kouzarides, T. Repression of RNA polymerase III transcription by the retinoblastoma protein. *Nature* 382:88–90; 1996.
 133. Whyte, P.; Buchkovich, K. J.; Horowitz, J. M.; Friend, S. H.; Raybuck, M.; Weinberg, R. A.; Harlow, E. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. *Nature* 334:124–129; 1988.
 134. Whyte, P., N. M. Williamson, and E. Harlow. Cellular targets for transformation by the adenovirus E1A proteins. *Cell* 56:67–75; 1989.
 135. Willis, I. M. RNA polymerase III. Genes, factors and transcriptional specificity. *Eur. J. Biochem.* 212:1–11; 1993.
 136. Wolf, V. J.; Dang, T.; Hartl, P.; Gottesfeld, J. M. Role of maturation-promoting factor (p34cdc2-cyclin B) in differential expression of the *Xenopus* oocyte and somatic-type 5S RNA genes. *Mol. Cell. Biol.* 14:4704–4711; 1994.
 137. Yoshinaga, S.; Dean, N.; Han, M.; Berk, J. A. Adenovirus stimulation of transcription by RNA polymerase III: Evidence for an E1A-dependent increase in transcription factor IIIC concentration. *EMBO J.* 5:343–354; 1986.

138. Yoshinaga, S. K.; Boulanger, P. A.; Berk, A. J. Resolution of human transcription factor TFIIC into two functional components. *Proc. Natl. Acad. Sci. USA* 84:3585–3589; 1987.
139. Yoshinaga, S. K.; L'Etoile, N. D.; Berk, A. J. Purification and characterization of transcription factor IIC2. *J. Biol. Chem.* 264:10726–10731; 1989.
140. Zhu, L.; van den Heuvel, S.; Helin, K.; Fattaey, A.; Ewen, M.; Livingston, D.; Dyson, N.; Harlow, E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. *Genes Dev.* 7:1111–1125; 1993.